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Abstract
Objectives To assess whether, in patients with normal liver
function, a hepatobiliary delay time of 10 min after Gd-EOB-
DTPA injection is sufficient for lesion characterisation.
Methods In 42 consecutive patients with suspected focal
liver lesions, dynamic MRI was performed after intravenous
Gd-EOB-DTPA, followed by hepatobiliary phases at 5, 10
and 20 min. The following items were assessed at each
hepatobiliary phase: parenchymal enhancement, contrast
agent excretion in bile ducts, lesion enhancement character-
istics (hypo-, iso-, or hyperintensity, rim enhancement, cen-
tral non-enhancement), and contrast- and signal-to-noise
ratios, separately for hypo- and hyperintense lesions.
Results Following enhancement, parenchymal signal inten-
sity increased significantly up to 10 min (86.3%, P<0.001),
and subsequently stabilised (86.5% after 20 min, P00.223).
Biliary contrast agent excretion was first observed in 2, 32
and 5 patients after 5, 10 and 20 min respectively. Hepato-
biliary lesion enhancement characteristics observed after
5 min persisted during later hepatobiliary phases. CNR
and SNR ratios increased significantly (P<0.05) up to
10 min after enhancement without further increase at
20 min, in hypo- and hyperintense lesions.
Conclusions If lesion characterisation is the primary reason
for performing MRI, a hepatobiliary delay time of 10 min
after Gd-EOB-DTPA injection is sufficient in patients with
normal liver function.
Key Points
• Magnetic resonance imaging is now a first line of investi-
gation of the liver.
• Optimal CNR and SNR are achieved 10 min after Gd-
EOB-DTPA injection.
• Typical enhancement characteristics are observed early
and do not change.
• Ten-minute hepatobiliary delay is sufficient for character-
isation of focal liver lesions.
Keywords Gd-EOB-DTPA . Examination time . Dynamic
contrast-enhanced MRI . Hepatobiliary imaging . Lesion
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Introduction
Gadolinium ethoxybenzyl diethylenetriaminepentaacetic ac-
id (Gd-EOB-DTPA) is a hepatocyte-specific contrast agent
for magnetic resonance imaging (MRI) of the liver, intro-
duced in 2004 (Bayer Schering Pharma, Berlin, Germany).
The additional value of Gd-EOB-DTPA compared with
other gadolinium-based contrast agents is the selective up-
take of contrast material by hepatocytes with subsequent
accumulation in the normal liver parenchyma, starting early
after the dynamic phase and reaching a plateau after 10–
20 min. Gd-EOB-DTPA differs from a similar hepatobiliary
gadolinium agent gadobenate dimeglumine (Gd-BOPTA,
Bracco Diagnostics, Princeton, NJ, USA) in two aspects:
the percentage of contrast agent excretion in the bile (50
versus 5%) and timing of the hepatobiliary phase (10–20
versus 60–120 min) [1, 2]. Thus, Gd-EOB-DTPA is the first
hepatobiliary MR contrast agent to allow acquisition of
dynamic imaging in the arterial, portal and venous phases
with a subsequent hepatobiliary phase in one examination
[3, 4].
C. S. van Kessel (*) :W. B. Veldhuis :
M. A. A. J. van den Bosch :M. S. van Leeuwen
Department of Radiology, University Medical Centre Utrecht,
Heidelberglaan 100,
3584CX Utrecht, The Netherlands
e-mail: c.s.vankessel@umcutrecht.nl
C. S. van Kessel
Department of Surgery, University Medical Centre Utrecht,
Utrecht, The Netherlands
Eur Radiol (2012) 22:2153–2160
DOI 10.1007/s00330-012-2486-2
Promising results have been published with increased
detection rates of especially small lesions after Gd-EOB-
DTPA-enhanced imaging [5–8]. Recently, Lowenthal et al.
observed higher detection rates for the hepatobiliary phases
compared with the dynamic phases, emphasising the added
value of the hepatobiliary phase [9].
Besides improved lesion detection, hepatobiliary images
also allow for improved lesion characterisation, especially
for differentiating hepatocellular lesions with functioning
bile ducts, such as focal nodular hyperplasia (FNH), which
exhibit iso- or hyperintensity during the hepatobiliary phase,
from hepatocellular lesions without bile ducts, such as ade-
nomas and most hepatocellular carcinomas, which lack en-
hancement in the hepatobiliary phase [10].
The duration of the time delay for the hepatobiliary phase is
a matter of discussion and is dependent on the rate of contrast
agent uptake by the hepatocytes [11]. The product brochure
advises a 20-min delay for evaluation of lesion detection and
characterisation, and most studies published so far obtained
their data at 20 min post-contrast injection. One study sug-
gested that an examination time of 10 min is sufficient for
accurate lesion detection in up to 61% of patients; however, no
recommendations were given on how to differentiate between
patients who should undergo imaging at 10 or at 20 min [12].
Another study reported contrast agent excretion in the com-
mon bile duct in 100% of non-cirrhotic livers after 20 min
versus 25% after 10 min [13].
Studies assessing the optimal timing for lesion character-
isation are not yet available. Several studies assessed en-
hancement patterns during Gd-EOB-DTPA-enhanced MRI
of different lesion types. However, most articles compared
results of unenhanced MRI with those of contrast-enhanced
MRI, without differentiation between dynamic and hepato-
biliary phases, leaving the additional value of the hepato-
biliary phases for lesion characterisation undefined [5–8].
Moreover, as these studies combined hepatobiliary phases at
various time delays, it is not possible to identify the diag-
nostic value of the individual delay times.
Thus, the purpose of the current study was to assess
whether, in patients with normal liver function, a hepatobili-
ary delay time of 10 min is sufficient for lesion character-
isation. Therefore, parenchymal enhancement, contrast
agent excretion in the bile ducts, lesion enhancement and
lesion characterisation at 5, 10 and 20 min post-Gd-EOB-
DTPA injection were compared.
Materials and methods
Patients
Between May 2007 and February 2010, 52 consecutive
patients underwent a total of 57 MRI of the liver with Gd-
EOB-DTPA for evaluation of known or suspected focal liver
lesions. Patients with a history of parenchymal disease (i.e.
cirrhosis, steatosis) or recent chemotherapy treatment were
excluded as these factors may influence liver function and
therefore Gd-EOB-DTPA uptake and excretion. This resulted
in a final inclusion of 42 patients for this retrospective analy-
sis: 36 patients with benign disease (focal nodular hyperplasia
n018, adenoma n09, haemangioma n02, cysts n02, unde-
fined benign lesions n03, no lesions n02), and 6 patients with
malignant disease (colorectal liver metastases n03, hepatocel-
lular carcinoma n01, intrahepatic cholangiocarcinoma n01,
oesophageal carcinoma metastases n01). Diagnosis of focal
liver lesions was histologically proven in 10 out of 42 patients
(FNH n01, hepatocellular carcinoma n01, adenoma n05,
colorectal liver metastases n03), either in surgically treated
patients or by a biopsy specimen. In the remaining patients, no
pathological confirmation was available, and these patients
received follow-up with ultrasound, CT or MRI to confirm
lesion diagnosis. Mean follow-up of these patients was
19 months (4–51 months), and one patient with an intrahe-
patic cholangiocarcinoma received only 2 months of follow-
up before dying of cancer-related causes.
The study was approved by the ethics committee, and
informed consent was waived as none of the patients was
subjected to any additional test.
MRI
MRI acquisitions of all patients were performed on a 1.5-
Tesla MRI (Philips, Best, The Netherlands) using a SENSE
Body Coil. The pre-contrast protocol consisted of the fol-
lowing sequences: breathhold T1-weighted turbo field echo
(TFE) images (transverse and coronal), T1-weighted in- and
out-of-phase images, free-breathing T1-weighted TFE
images and free-breathing T2-weighted images (see Table 1).
Administration of Gd-EOB-DTPA (25 μmol/kg) was carried
out as a bolus with a rate of 2 mL/s through an intravenous
cubital line, followed by a 25-mL saline chaser. After bolus
injection, T1-weighted 3D-TFE was performed sequentially
at 20, 60 and 180 s (dynamic phases) and at 5, 10 and
20 min post-contrast injection (hepatobiliary phases 5, 10
and 20 min respectively). Limited availability of MRI
equipment precluded the acquisition of the 20-min series
in 18/42 patients (43%). In these patients the entire MRI
examination, including the 5- and 10-min series, was al-
ready assessed as being diagnostic. All images were ac-
quired in the transverse plane with a section thickness of
4 mm, reconstructed every 2 mm. MRI data were stored in
the Picture Archiving and Communication System (PACS)
at the UMC Utrecht (Easy Vision Workstation, Philips Med-
ical Systems, Best, The Netherlands), and further assess-
ment of MRI acquisitions was performed on clinical PACS
workstations.
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Parenchymal contrast agent accumulation and contrast agent
excretion in the bile
All MRI images were evaluated in order to obtain data on
liver signal intensity, lesion signal intensity, muscle signal
intensity and contrast agent excretion in the bile. The signal
intensity measurements were performed on the pre-contrast
acquisition and on each post-contrast phase by one investi-
gator (C.v.K., research fellow). Signal intensity of the liver
parenchyma was measured at three different points in the
liver (in the right and left hemi-liver and at the midportion of
the liver) in order to obtain an average signal intensity per
sequence (mean SIliver). Signal intensity measures were
obtained by means of circular, operator-defined regions of
interest (ROI, approximately 100 mm2) avoiding any ves-
sels, lesions or peripheral perfusion abnormalities. Measure-
ments were performed at the same anatomical location on
each sequence. The relative increase in mean SIliver in time
was measured in terms of percentage: (mean SIliver post/mean
SIliver pre)×100%. The SI of the background noise was
measured in an ROI that was placed just ventral to the liver
and outside the body along the phase-encoding direction
(ROI approximately 500 mm2).
Lesion signal intensity was measured once, and the ROI
was set to contain as much of the lesion as possible, avoid-
ing areas of necrosis or haemorrhage. Lesion-to-liver
contrast-to-noise ratios (CNR) were calculated as follows:
(SIliver−SIlesion)/SDnoise. Also, signal-to-noise ratios (SNR)
were calculated as follows: SIlesion/SDnoise. Analyses during
the hepatobiliary phases were performed separately for
hypointense and hyperintense lesions.
Furthermore, signal intensity of the left erector spinae
muscle (SImuscle) was determined at each dynamic sequence,
including the pre-contrast sequence. These intensity meas-
ures were used as the reference signal intensity for the liver.
Relative increase in signal intensity of the erector spinae
muscle was calculated [(SImuscle post/SImuscle pre)×100%].
Liver-to-muscle contrast ratios (L-M ratios) were calculated
as follows: L-M ratio0mean SIliver/SImuscle.
All hepatobiliary phases of each patient were assessed for
contrast agent excretion in the bile ducts [13]. Contrast
agent excretion was defined as contrast agent visible in the
common bile duct.
Enhancement characteristics
In order to ascertain the optimal delay time to assess the
individual hepatobiliary enhancement patterns of the vari-
ous liver lesions, 5-, 10- and 20-min hepatobiliary series
were evaluated consecutively. Enhancement patterns were
assessed by two observers in consensus (M.v.L. and C.v.K.).
Enhancement patterns were categorised as isointense,
hypointense or hyperintense relative to the normal liver
parenchyma. In addition, heterogeneity, presence of
rim enhancement or areas of linear or nodular non-
enhancement were recorded.
Statistical analysis
Data on signal intensities were displayed as mean±standard
error (percentages) or median with interquartile range (IQR;
absolute values). Normal distribution of the data was tested
Table 1 MRI pulse sequence protocol used during the study period: 1.5 T MRI, dedicated torso coil
Pulse sequence Plane TR TE Flip FOV (mm) Gap (mm) Slice (mm) Matrix
SURVEY insp Axial 2.5 1.27 50 450 3.5 8 192×144
SURVEY exp Axial 2.5 1.27 50 450 3.5 8 192×144
Refscan Axial 8.0 0.57 56×40
T1 TFE bh, insp Axial 8.5 4.2 10 450 0 10 256×128
T1 TFE bh, insp Sagittal 8.5 4.2 10 450 0 10 256×128
T1 TFE bh, insp Coronal 8.5 4.2 10 450 0 10 256×128
T1 TFE bh in+out of phase Axial 181 2.3/4.6 80 375 1 7 224×134
T2 TSE RT Axial 556 80 90 405 1 7 400×215
T1 FFE RT Axial 10 4.6 15 405 1 7 256×126
T2 TSE SSH Axial 8,000 800 90 300 40 320×256
EPI-DWI b00, 50 fb, RT Axial 4,095 56 85 360 0 5 128×83
EPI-DWI b00, 500 fb, RT Axial 4,095 56 85 360 0 5 128×83
THRIVE bh (pre-contrast; 25 and 60 s; 3, 5, 10 and 20 min)a Axial 3.7 1.76 10 450 −2 4 176×124
TR Repetition time, TE echo time, flip flip angle, FOV field of view, slice slice thickness, exp expiratory, insp inspiratory, TFE turbo field echo, TSE
turbo spin echo, FFE fast field echo, EPI echo planar imaging, SSH single shot, RT respiratory triggered, bh breath hold, fb free breathe, THRIVE
T1-weighted high resolution isotropic volume examination
a After injection of Gd-EOB-DTPA-DTPA 0.25 μmol/kg at 2 ml/s
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using the Shapiro-Wilk’s test for normality and histograms.
In parametric data, paired t-tests were used to test for sig-
nificant differences in signal intensities of the liver, lesions,
muscle, L-M ratios, CNRs and SNRs among 5, 10 and
20 min post-Gd-EOB-DTPA injection. In non-parametric
data, the Wilcoxon signed ranks test was used. Statistical
analyses were performed with commercially available soft-
ware (SPSS version 15.0 for Windows, SPSS, Chicago, IL,
USA). Statistical significance was set at a P value of less
than 0.05. All analyses were performed in agreement with
our in-house statistician.
Results
Patients and timing of delayed images
Three patients received two MRI during the study period as
individual follow-up was clinically warranted. In those three
patients, only the first MRI was included to prevent dispro-
portionate contribution of these patients to the data. This
resulted in a total of 42 MRI that were available for further
analysis. Early hepatobiliary phase imaging at 5 and 10 min
post-Gd-EOB-DTPA injection were obtained in all 42
patients, while 20-min imaging was obtained in 24/42
(57%) patients.
Contrast agent excretion in the bile
Contrast agent excretion in the common bile duct was
observed in 2/42 (4.8%) patients after 5 min and in 34/42
(80.9%) patients after 10 min. After 20 min, contrast agent
excretion was observed in 21/24 patients, thereby resulting
in a total of 39/42 (92.9%) patients showing contrast agent
excretion at either 10 or 20 min post-contrast agent injec-
tion. Three patients did not show contrast agent excretion at
any available sequence. The absence of contrast agent ex-
cretion could be explained in one patient by the presence of
intrahepatic cholangiocarcinoma causing bile obstruction, in
the second patient by the presence of multiple large adeno-
mas affecting almost 70% of the liver parenchyma, whilst in
the third patient no straightforward explanation for the
delayed contrast agent excretion could be identified.
Parenchymal enhancement
Compared with pre-contrast SIliver, the median relative in-
crease in SIliver at 5, 10 and 20 min was 75.1% (IQR 18.6),
86.3% (IQR 28.8) and 86.5% (IQR 34.0) respectively. The
difference between 5 and 10 min was significant (P<0.001),
whilst the difference between 10 and 20 min was not sig-
nificant (P00.223). Signal intensity of the M. erector spinae
was variable over time (see Fig. 1), with a significant
decrease in signal intensity between 10 min (17.7%, IQR
12.4) and 20 min (4.1%, IQR 10.74; P<0.001). This
resulted in significant elevation of relative L-M ratios (%)
at 5, 10 and 20 min (52.5±3.7, 59.7±3.6 and 77.65±6.5%
respectively) compared with pre-contrast sequences. The
increases between 5 and 10 min and between 10 and
20 min were both significant (P<0.001). However, the large
difference between 10 and 20 min was mostly caused by the
difference in relative signal intensity of the muscle at 10 min
(17.7%) and 20 min (4.1%).
Fig. 1 Mean (±SE) relative increase in signal intensities over time
compared with the pre-contrast imaging. Results are displayed for the
liver, the muscle and the liver-muscle ratios
Fig. 2 aMean contrast-to-noise ratios with standard error of the mean
at 5, 10 and 20 min compared with the pre-contrast images. b Mean
signal-to-noise ratios with standard error of the mean at 5, 10 and
20 min compared with the pre-contrast images
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The SNR and CNR were separately assessed for hyper-
and hypointense lesions in the hepatobiliary phase respec-
tively (Fig. 2a, b). For hyperintense lesions, CNRs at 5, 10
and 20 min were significantly increased compared with pre-
contrast images (P<0.05). However, CNRs were highest at
10 min, and a significant reduction was observed at 20 min
(P00.039). SNRs showed a similar pattern: SNRs at 5, 10
and 20 min were significantly higher compared with pre-
contrast images; however, SNRs were highest at 10 min
while SNRs at 5 and 20 min were similar (P00.620). In
hypointense lesions CNRs were significantly increased in
the hepatobiliary phases compared with pre-contrast images
(P<0.05), but CNRs did not further improve between 5 and
10 min (P00.355), or between 10 and 20 min (P00.323;
Fig. 3 a-d Various enhancement patterns of solid hypervascular
lesions during early dynamic phases and hepatobiliary phases
(25 and 60 s; 3, 5, 10 and 20 min). a A 48-year-old man received an
MRI with Gd-EOB-DTPA after he presented with an incidental lesion
on ultrasound. The MRI shows a lesion in segments 4 and 8 of the
liver, demonstrating the classic pattern of a focal nodular hyperplasia:
hyperintense in the arterial phase, isointense in the portal phase, fol-
lowed by a hyperintense appearance due to accumulation of contrast
agent from 3 min onward, persisting into the later hepatobiliary phases.
Furthermore, central linear non-enhancing structures in the hepatobili-
ary phases represent a central scar. The lesion remained stable in size
during a 1.5-year follow-up. b A 59-year-old woman underwent ab-
dominal CT during follow-up of a colorectal carcinoma. The lesion in
segment 8 showed the following characteristics on MRI with Gd-EOB-
DTPA: hyperintense on the arterial and portal phases with central
hypointensity. After 3 min the central hypointense area enlarges, sur-
rounded by a suggestion of contrast agent accumulation at the periph-
ery of the lesion. During the later hepatobiliary phases the lesion centre
becomes more hypointense compared with the liver parenchyma, and
now unequivocal contrast agent accumulation at the periphery of the
lesion is observed. These characteristics can occur in an atypical focal
nodular hyperplasia (FNH) [10]. However, this patient had a history of
malignancy and was therefore scheduled for surgery. Histopathology
revealed FNH. c A 78-year-old man presented with the diagnosis of
FNH based on a previous CT. A Gd-EOB-DTPA MRI was performed,
showing a hypervascular lesion, with a central, non-enhancing cleft
during the arterial phase, suggestive of a scar. During the portal phase,
the central cleft remains, whilst the larger portion of the lesion is
hypointense relative to surrounding parenchyma signifying wash-out.
There is no contrast agent uptake during the subsequent hepatobiliary
phases. As wash-out and non-accumulation in the late phases are
atypical of FNH, a biopsy was performed. Histopathology revealed a
well-differentiated hepatocellular carcinoma. d A 41-year-old woman
presented with abdominal pain. Ultrasound revealed two large lesions
in the right hemi-liver, and an MRI with Gd-EOB-DTPA was per-
formed. The lesions are hyperintense on the arterial phase, iso-
intense on the portal phase and homogeneously hypointense during
all hepatobiliary phases. Thus, there is no contrast agent accumulation,
and there are no signs of a central scar. This is an atypical finding,
consistent with a hepatocellular adenoma or hepatocellular carcinoma.
The patient underwent surgery, and histopathology revealed two hepa-
tocellular adenomas
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Fig. 2a, b). SNRs increased significantly compared with pre-
contrast images (P<0.05), however, compared with 5-min
images, SNRs did not further improve at 10 min (P00.325)
and 20 min (P00.937).
Enhancement characteristics
In 20 out of 42 patients multiple lesions were present, and in
these patients enhancement characteristics of the various
lesions were similar. Patients with multiple lesions presented
either with adenomas (12/20), FNHs (6/20), or with colo-
rectal liver metastases (2/20). In 17 patients lesions were
identified with an overall hyperintense appearance during
the hepatobiliary phases; in 5/17 (29%) patients the lesions
were homogeneously hyperintense, in 4/17 (24%) patients
the lesions showed heterogeneous hyperintensity with areas
of hypointensity, in 7/17 (41%) patients the lesions were
hyperintense with a central cleft-like hypointensity and 1
patient presented with a lesion with a narrow, peripheral
hyperintense border, surrounding the hypointense central
part of the lesion (shown in Fig. 3b). In all 17 patients, the
observed enhancement characteristics at 5 min persisted
during the later phases.
Another 18 patients presented with lesions with an hypo-
intense appearance during the hepatobiliary phases. Most
patients presented with homogeneously hypointense lesions
(n017), and one patient presented with a lesion with a
marked hypointense lesion centre. Again, these enhance-
ment characteristics were observed after 5 min and persisted
during later phases in all 18 patients.
Another patient presented with a solitary lesion that was
only visible during the arterial phase and appearing isoin-
tense during all hepatobiliary phases. Four patients pre-
sented with lesions smaller than 5 mm that were too small
to allow determination of the enhancement characteristics.
In two patients no lesions could be detected.
In summary, the observed enhancement characteristics
after 5 min, i.e. hypo-, iso- or hyperintense relative to the
surrounding parenchyma, persisted after 10 and 20 min in
all 36 patients harbouring lesions larger than 5 mm. Like-
wise, the presence of areas of non-enhancement or the
presence of peripheral rim enhancement, once noted at the
5-min hepatobiliary phase, persisted during the later phases
in all patients (Fig. 3).
Discussion
The advantage of Gd-EOB-DTPA in combining early dy-
namic imaging with late, hepatobiliary phase imaging in one
examination comes at the cost of the additional time re-
quired to obtain optimal lesion-to-liver contrast in the hep-
atobiliary phase.
In order to minimise examination duration the order of
sequences can be adjusted. T2-weighted sequences can be
acquired during the accumulation phase, however, once Gd-
EOB-DTPA is excreted in the bile, the signal in the bile
ducts will be lowered hampering assessment of the biliary
tree during the hepatobiliary phase [8, 14, 15]. Nonetheless,
if acquired immediately after the dynamic series, before
biliary enhancement occurs, image quality is not impaired
[14]. The T2-weighted imaging characteristics of lesions are
not significantly influenced if acquired during the hepato-
biliary phase [16]. Indeed, because of the lowering of the
T2-weighted signal of the normal parenchyma in the hep-
atobiliary phase, lesion conspicuity may actually improve
[16, 17]. Signal intensity on diffusion-weighted sequences is
also not influenced in the accumulation phase, resulting in
Fig. 4 a-f In this patient, an
additional lesion was detected
at 20 min post-contrast injec-
tion. An adenoma in segment 6
is clearly visible at a 5, b 10 and
c 20 min post-contrast injection.
f An additional lesion was
detected in segment 6 at 20 min
post-contrast injection. In retro-
spective evaluation, with
knowledge of the presence of
this lesion at 20 min, a subtle
hypointensity already reflects
the presence of the lesion at d 5
and e 10 min
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equivalent lesion conspicuity and apparent diffusion coeffi-
cients before and after Gd-EOB-DTPA injection [17–19].
These adjustments in the protocol can lead to a time reduc-
tion of several minutes.
In addition to rearranging the order of imaging sequen-
ces, the delay of the hepatobiliary phase should be limited to
the time needed to achieve diagnostic image quality that
allows adequate lesion characterisation and detection.
In this study, it is shown that in patients with normal
functioning liver parenchyma, a delay time of 10 min after
Gd-EOB-DTPA injection is sufficient to achieve adequate
enhancement of the liver parenchyma. Contrast agent excre-
tion in the bile ducts was visible in 81% of patients at
10 min suggesting contrast agent saturation of the paren-
chyma. The relative increase in parenchymal signal intensity
between 5 and 10 min was statistically significant (75.1% at
5 min vs. 86.3% at 10 min respectively), whilst an additional
20-min series did not further increase the signal intensity.
Lesion characterisation and lesion detectability are
parameters that are clinically more relevant than parenchy-
mal enhancement. To our knowledge no studies have
reported on the relative value of the various hepatobiliary
delay times on lesion enhancement and characterisation.
The current study shows that the individual hepatobiliary
enhancement pattern, be it hypointense or hyperintense,
depending on the type of lesion, is already observed after
5 min post-contrast injection. Once present, the observed
individual enhancement pattern does not change thereafter
and persists at the 10- and 20-min delay time. Also, in
hypointense lesions, CNRs peaked at 10 min and then
stabilised at 20 min, while SNRs showed a peak already at
5 min and then declined. In hyperintense lesions, both
CNRs and SNRs were highest at 10 min and then decreased
at 20 min. This again suggests that for characterisation of
lesions an examination time of 10 min is sufficient.
Regarding lesion detection, Motosugi et al. assessed
whether it was possible to shorten the examination of the
hepatobiliary phase to 10 min for imaging of (malignant)
focal liver lesions, while maintaining adequate lesion detec-
tion [12]. They concluded that an examination time of
20 min could be omitted in 61% of cases, without loss of
accuracy for lesion detection. A post-hoc analysis of the 24
patients in our study who received both 10- and 20-min
acquisitions substantiated these results; the addition of
20 min to the combination of 5 and 10 min resulted in
detection of six additional lesions in two patients (see
Fig. 4.). Both of these patients were already diagnosed with
multiple large adenomas, and the additional 10 minf led to
the detection of six additional subcentimetre adenomas. No
additional lesions were detected in the remaining 22
patients.
There are several limitations to this study. The patient
selection is a skewed sample of the general population of
patients with focal liver lesions, as there were 36 patients
with benign lesions and only 6 patients with malignant
lesions. However, this distribution reflects the main use of
Gd-EOB-DTPA in our hospital, i.e., characterisation of solid
liver lesions and especially the differentiation of FNH,
which does not require treatment or follow-up, from other
pathological conditions that do require further medical
attention.
All patients underwent hepatobiliary phase acquisitions
after 5 and 10 min. Because of the limited availability of the
time slots for MRI, the hepatobiliary phase after 20 min was
performed in only 24 out of 42 patients. In the remaining
patients in whom the 20-min acquisition was not obtained,
the combined 5- and 10-min series were already assessed as
being diagnostic. However in the ideal situation all patients
would have undergone 5-, 10- and 20-min imaging.
The ROIs of the erector spinae muscle were used as a
reference to calculate liver-to-muscle ratios. Other articles
assessing dynamic imaging (after Gd-EOB-DTPA) have
used liver-to-spleen ratios to evaluate the degree of liver
parenchymal enhancement, as the spleen is not affected by
parenchymal diseases like the liver and contrast agent up-
take is therefore not affected [12]. In this study, contrast
enhancement of the spleen was fairly irregular, increased
until 180 s and from that point gradually decreased (data not
shown). Therefore, we used liver-to-muscle ratios with the
erector spinae muscle as the reference, as reported in other
articles [11, 20]. Nevertheless, our data showed a transient
increase in contrast enhancement between 60 s and 10 min,
which implies that the interstitial enhancement component
of the muscle is delayed compared with that of the liver.
In conclusion, this study combined information on con-
trast agent uptake, contrast agent excretion and lesion en-
hancement characteristics. The results show that in patients
without a history of chronic liver disease, steatosis or pre-
vious chemotherapy, a hepatobiliary delay time of 10 min
after Gd-EOB-DTPA injection is sufficient if lesion charac-
terisation is the main purpose of the study.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
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